

Ana I Casas

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/11624003/publications.pdf>

Version: 2024-02-01

17
papers

1,397
citations

623734

14
h-index

888059

17
g-index

21
all docs

21
docs citations

21
times ranked

2132
citing authors

#	ARTICLE	IF	CITATIONS
1	Network pharmacology: curing causal mechanisms instead of treating symptoms. Trends in Pharmacological Sciences, 2022, 43, 136-150.	8.7	294
2	European contribution to the study of ROS: A summary of the findings and prospects for the future from the COST action BM1203 (EU-ROS). Redox Biology, 2017, 13, 94-162.	9.0	242
3	From single drug targets to synergistic network pharmacology in ischemic stroke. Proceedings of the National Academy of Sciences of the United States of America, 2019, 116, 7129-7136.	7.1	132
4	Reactive Oxygen-Related Diseases: Therapeutic Targets and Emerging Clinical Indications. Antioxidants and Redox Signaling, 2015, 23, 1171-1185.	5.4	120
5	NOX4-dependent neuronal autotoxicity and BBB breakdown explain the superior sensitivity of the brain to ischemic damage. Proceedings of the National Academy of Sciences of the United States of America, 2017, 114, 12315-12320.	7.1	112
6	Pharmacology and Clinical Drug Candidates in Redox Medicine. Antioxidants and Redox Signaling, 2015, 23, 1113-1129.	5.4	75
7	On the Clinical Pharmacology of Reactive Oxygen Species. Pharmacological Reviews, 2020, 72, 801-828.	16.0	70
8	Simultaneous determination of 8 neurotransmitters and their metabolite levels in rat brain using liquid chromatography in tandem with mass spectrometry: Application to the murine Nrf2 model of depression. Clinica Chimica Acta, 2016, 453, 174-181.	1.1	55
9	Calcium-dependent blood-brain barrier breakdown by NOX5 limits postreperfusion benefit in stroke. Journal of Clinical Investigation, 2019, 129, 1772-1778.	8.2	55
10	Isoform-selective NADPH oxidase inhibitor panel for pharmacological target validation. Free Radical Biology and Medicine, 2020, 148, 60-69.	2.9	50
11	A disease cluster-based drug repurposing of soluble guanylate cyclase activators from smooth muscle relaxation to direct neuroprotection. Npj Systems Biology and Applications, 2018, 4, 8.	3.0	45
12	Early toll-like receptor 4 blockade reduces ROS and inflammation triggered by microglial pro-inflammatory phenotype in rodent and human brain ischaemia models. British Journal of Pharmacology, 2019, 176, 2764-2779.	5.4	44
13	Network medicine for disease module identification and drug repurposing with the NeDRex platform. Nature Communications, 2021, 12, 6848.	12.8	39
14	Time-dependent dual effect of NLRP3 inflammasome in brain ischaemia. British Journal of Pharmacology, 2022, 179, 1395-1410.	5.4	19
15	NOS knockout or inhibition but not disrupting PSD-95-NOS interaction protect against ischemic brain damage. Journal of Cerebral Blood Flow and Metabolism, 2016, 36, 1508-1512.	4.3	18
16	Data supporting the rat brain sample preparation and validation assays for simultaneous determination of 8 neurotransmitters and their metabolites using liquid chromatography-tandem mass spectrometry. Data in Brief, 2016, 7, 714-720.	1.0	12
17	Implication of type 4 NADPH oxidase (NOX4) in tauopathy. Redox Biology, 2022, 49, 102210.	9.0	12